National Pharmaceutical Strategy

1
National Pharmaceutical Strategy

• What is it what should you know about it?
• National Advocacy Leadership Forum 2006
• 4 June 2006, Ottawa

2
Concept isnt new

• October 2002 -- Kirbys Senate report on future
  of healthcare.
• November 2002 -- Romanows Building on Values
  the future of Health Care in Canada.
• February 2003 -- Accord on Health Care Renewal
  federal commitment to increase healthcare
  spending over 5 years.
• November 2003 -- Council of Federation created.
  Increasing government concern over rate of growth
  in drug plan costs
• Spring 2004 Liberal Partys wait-time reduction
  plan also included a catastrophic drug plan.
• July 2004 -- Council of Federation
  Niagara-on-the-Lake proposal for national
  pharma-care program.
• September 2004 -- Ten Year Health Accord Task
  Force to review NPS also includes reference to a
  national catastrophic drug plan.
• November 2005 NDP election platform
  specifically calls for a national catastrophic
  drug plan. All party support for some sort of
  drug plan that ensures Canadians ae not unduly
  burdened by costs of prescribed medications.

3
National Pharmaceutical Strategy

• F/P/T Health Ministers created working group with
  mandate to report back on nine components by June
  2006.
• catastrophic drug coverage
• national drug formulary
• accelerated access to breakthrough
  drugs/improvement to drug approval process
• strengthened evaluation of drug safety
  effectiveness
• purchasing strategies
• influencing prescribing behaviour
• increase e-prescribing with electronic health
  records
• increase access to generics achieve
  international parity on prices of non-patented
  drugs
• enhanced analysis of cost-drivers cost
  effectiveness

4
Whos in charge?

• Co-chaired by Federal BC Ministers of Health.
• BC coordinates operations of three working groups
  who meet regularly report periodically to the
  Federal BC co-chairs.

5
Changing policy environment

• Bill 102 in Ontario.
• Common Drug Review announcement of public members
  appointed to drug review committee by fall 2006.
• New federal government with desire to focus on
  core jurisdictional responsibilities.

6
Three working groups

• Access co-chaired by Feds PEI
• catastrophic coverage
• improve access to breakthrough drugs
• national formulary
• Safety Effectiveness co-chaired by Feds
  Ontario
• strengthen evaluation of safety effectiveness
• influencing prescribing behaviours
• analysis of cost-drivers cost-effectiveness
• e-prescribing electronic health records
• Price Purchasing co-chaired by Feds Alberta
• purchasing strategies
• access to generics intl parity on prices of
  non-patented drugs

7
NPS information sessions

• Co-chairs confirmed only 5 priority areas
  reporting to Ministers by June 30
• National Catastrophic Drug Plan
• Expensive Drugs for Rare Diseases
• Expansion of the Common Drug Plan
• Real World Safety Effectiveness
• Pricing Purchasing Strategies

8
NPS next steps

• Report to Ministers by 30 June 2006.
• Ministers review in July 2006.
• Potentially 2 - maybe 3 - papers released in
  August for public discussion
• Real World Safety Effectiveness
• Expensive Drugs for Rare Diseases
• National Catastrophic Drug Plan
• What will our Association say?

9
Associations position

• Draft NPS principles developed in discussions
  with small working groups key individuals
  across Association.
• NAC recommend minor change.
• What do you think?
• Questions?

10
THANK YOU!

• For further information, please contact
• Karen Philp, Executive Director
• Public Policy Government Relations
• Canadian Diabetes Association
• Telephone [phone]
• Or 416-408-7041